Abstract: The present invention relates to an electric wheelchair having a voice recognition drive system comprising: a traveling apparatus main body unit which has a plurality of wheels in a lower end thereof; a seating unit which is installed in an upper end of the traveling apparatus main body unit so as to be able to be lifted; an auxiliary robot leg unit which is able to be inserted into and protrude from the traveling apparatus main body unit, and which includes multi-joint driven by an external force; and a voice recognition drive unit which extracts a preset command from an externally input voice, and which drives the plurality of wheels, lifts the seating unit, and drives the auxiliary robot leg unit.

Abstract: The present invention relates to phytosphingosine-1-phosphate micelle nanoparticles having high transdermal penetration and absorption rates. In addition, the present invention relates to a cosmetic composition containing the micelle nanoparticles and a skin care method using the same.

Abstract: The present invention relates to phytosphingosine-1-phosphate micelle nanoparticles having high transdermal penetration and absorption rates. In addition, the present invention relates to a cosmetic composition containing the micelle nanoparticles and a skin care method using the same.

Abstract: The present invention relates to an electric wheelchair having a voice recognition drive system comprising: a traveling apparatus main body unit which has a plurality of wheels in a lower end thereof; a seating unit which is installed in an upper end of the traveling apparatus main body unit so as to be able to be lifted; an auxiliary robot leg unit which is able to be inserted into and protrude from the traveling apparatus main body unit, and which includes multi-joint driven by an external force; and a voice recognition drive unit which extracts a preset command from an externally input voice, and which drives the plurality of wheels, lifts the seating unit, and drives the auxiliary robot leg unit.

Abstract: Disclosed is a diffuser controller for tidal stream power generation, for use in a tidal stream power generator installed under water to generate electricity using a tidal stream. The diffuser controller includes: a turbine configured to be rotated by the tidal stream; a diffuser which is formed with an inlet through which a fluid flows into the diffuser and an outlet through which the fluid flows out from the diffuser, the turbine being fixed inside the diffuser and a rear foil being rotatably installed in the outlet; and a control unit configured to adjust an rotating angle of the rear foil depending on a direction or velocity of the tidal stream. The diffuser is configured to be rotatable.

Abstract: Printed circuit boards and breadboard devices have contact pads and magnetic component connectors where connection between the contact pads and the magnetic component connectors are made by magnetic force. Either the contact pad or the magnetic component connector will be magnetic and the other will be made of a material to which a magnet will be attracted. For example, printed circuit boards, which usually have copper traces, include contact pads made of a material to which a magnet will be attracted. Circuit components are connected to magnetic component connectors having magnetic legs which then connect the components to the contact pads of the circuit board or breadboard device. This makes the connection of components to a printed circuit board or breadboard device fast and easy and provides for easy removal and replacement of components. Magnetic component connectors can also be configured to connect magnetically to one another.

Abstract: Printed circuit boards and breadboard devices have contact pads and magnetic component connectors where connection between the contact pads and the magnetic component connectors are made by magnetic force. Either the contact pad or the magnetic component connector will be magnetic and the other will be made of a material to which a magnet will be attracted. For example, printed circuit boards, which usually have copper traces, include contact pads made of a material to which a magnet will be attracted. Circuit components are connected to magnetic component connectors having magnetic legs which then connect the components to the contact pads of the circuit board or breadboard device. This makes the connection of components to a printed circuit board or breadboard device fast and easy and provides for easy removal and replacement of components. Magnetic component connectors can also be configured to connect magnetically to one another.

Abstract: Provided are electrical components and a breadboard for an electronic circuit study kit.

Abstract: Printed circuit boards and breadboard devices have contact pads and magnetic component connectors where connection between the contact pads and the magnetic component connectors are made by magnetic force. Either the contact pad or the magnetic component connector will be magnetic and the other will be made of a material to which a magnet will be attracted. For example, printed circuit boards, which usually have copper traces, include contact pads made of a material to which a magnet will be attracted. Circuit components are connected to magnetic component connectors having magnetic legs which then connect the components to the contact pads of the circuit board or breadboard device. This makes the connection of components to a printed circuit board or breadboard device fast and easy and provides for easy removal and replacement of components. Magnetic component connectors can also be configured to connect magnetically to one another.

Abstract: Effective anticancer agents for use in treatment of particular cancers can be predicted by testing whether particular anticancer agents are effective in reducing the lactic acid production by sample cells removed from the particular cancerous tissue to be treated. Similarly, effective anticancer agents can be predicted by testing whether particular anticancer agents are effective in reducing ATP levels in sample cells removed from the particular cancerous tissue. A method of predicting anticancer agents that will be effective for use in treating a particular cancer includes the steps of obtaining a plurality of samples of the cancerous tissue to be treated and determining the capacity of a sample to produce lactic acid in both the presence and absence of a particular anticancer agent. Anticancer agents that most reduce the lactic acid production should be effective treatment agents.

Abstract: Printed circuit boards and breadboard devices have contact pads and magnetic component connectors where connection between the contact pads and the magnetic component connectors are made by magnetic force. Either the contact pad or the magnetic component connector will be magnetic and the other will be made of a material to which a magnet will be attracted. For example, printed circuit boards, which usually have copper traces, include contact pads made of a material to which a magnet will be attracted. Circuit components are connected to magnetic component connectors having magnetic legs which then connect the components to the contact pads of the circuit board or breadboard device. This makes the connection of components to a printed circuit board or breadboard device fast and easy and provides for easy removal and replacement of components. Magnetic component connectors can also be configured to connect magnetically to one another.

Abstract: Hydrogels containing catalase co-immobilized with an analyte-sensitive enzyme such as glucose oxidase are disclosed. The hydrogels may be pH-sensitive, and preferably are thin and lightly crosslinked. The catalase is present in concentrations ranging generally from 100 units/ml to about 1000 units/ml. These hydrogels have much faster swelling response times as compared to hydrogels without catalase, and are useful in biosensors and analyte-responsive drug delivery devices. The hydrogels also have an increased useful life, due to protection of the immobilize analyte-sensitive enzyme from degradation by hydrogen peroxide.

Abstract: An implantable biosensor for detecting an analyte in vivo in body fluids comprises an analyte-sensitive hydrogel filament chemically configured to vary its displacement volume according to changes in concentration of an analyte, such as glucose, in a patient's body fluid. A photometric displacement transducer placed inside the biosensor is configured to quantifiably detect changes in the displacement volume of the hydrogel filament, such as by detecting the light intensity on a photoreceptor arranged to receive light of varying intensity depending upon the displacement of the hydrogel filament. A battery powered telemeter operably engaged to the photometric displacement transducer sends a radio data signal representing glucose concentration level to a receiver containing an alarm system. The alarm system can automatically notify a person that the analyte level is outside desired predetermined parameters, and/or to automatically inject an agent to counteract the adverse analyte levels.

Abstract: The present invention relates to a controlled drug release system in which a certain ratio or retinoic acid is incorporated into a microsphere comprising biodegradable polymer and amphoteric block copolymer having both hydrophilic and hydrophobic groups.

Abstract: An implantable chip biosensor for detecting an analyte in vivo in body fluids comprises an analyte-sensitive hydrogel slab chemically configured to vary its displacement volume according to changes in concentration of an analyte, such as glucose, in a patient's body fluid, the slab being disposed in a groove in a support block. The biosensor chip is ‘read’ by an external scanner configured to quantifiably detect changes in the displacement volume of the hydrogel slab. The support block is made of rigid or semi-rigid support material to restrain expansion of the hydrogel in all but one dimension, and the groove has one or more openings covered with a semipermeable membrane to allow contact between the patient's body fluid and the hydrogel. The scanning means may be any type of imaging devices such as an ultrasound scanner, a magnetic resonance imager (MRI), or a computerized tomographic scanner (CT) capable of resolving changes in the slab's dimensions.

Abstract: The penicillin biosensor (10) has a pH-sensitive polymeric hydrogel (30) in a rigid enclosure (20). The hydrogel includes an immobilized enzyme such as penicillinase. The enzyme catalyzes a chemical reaction consuming penicillin and producing penicillic acid. The hydrogel changes its osmotic pressure in proportion to the concentration of the penicillic acid. By measuring the change in osmotic pressure with a pressure transducer (40), the biosensor (10) is able to accurately measure the concentration of penicillin. A battery (64) powered monitoring device, connected to the biosensor (10) through electrical wires, is operably programmed to display the penicillin concentration in a computer (62) as well as to activate LED or buzzer as an alert in case that the measured concentration of penicillin is over the threshold concentration.

Abstract: An implantable chip biosensor for detecting an analyte in vivo in body fluids comprises an analyte-sensitive hydrogel slab chemically configured to vary its displacement volume according to changes in concentration of an analyte, such as glucose, in a patient's body fluid, the slab being disposed in a groove in a support block. The biosensor chip is ‘read’ by an external scanner configured to quantifiably detect changes in the displacement volume of the hydrogel slab. The support block is made of rigid or semi-rigid support material to restrain expansion of the hydrogel in all but one dimension, and the groove has one or more openings covered with a semipermeable membrane to allow contact between the patient's body fluid and the hydrogel. The scanning means may be any type of imaging devices such as an ultrasound scanner, a magnetic resonance imager (MRI), or a computerized tomographic scanner (CT) capable of resolving changes in the slab's dimensions.

Abstract: A biosensor (10) has a hydrogel (30) in a rigid and preferably biocompatible enclosure (20). The hydrogel (30) includes an immobilized analyte binding molecule (ABM) and an immobilized analyte. The immobilized analyte competitively binds with free analyte to the ABM, thus changing the number of crosslinks in the hydrogel (30), which changes hydrogel swelling tendency (and thus the osmotic pressure) in its confined space in proportion to the concentration of free analyte concentration. By measuring the change in hydrogel pressure with a pressure transducer (40), the biosensor (10) is able to accurately measure the concentration of the free analyte molecule without the problem of oxygen limitations and interference encountered by prior art biosensors. A battery (64) powered telemeter (60) operably engaged to the pressure transducer (40) sends a radio data signal to a receiver (66) containing an alarm system operably attached to a computer (62).

Abstract: A biosensor (10) has a hydrogel (30) in a rigid and referably biocompatible enclosure (20). The hydrogel (30) includes an immobilized glucose-binding molecule such as concanavalin A (Con A) and an immobilized hexose saccharide such as a-D-mannopyranoside. The immobilized hexose saccharide competitively binds with free glucose to the glucose-binding molecules, thus changing the number of crosslinks in the hydrogel (30), which changes hydrogel swelling tendency and the pressure of the hydrogel in its confined space in proportion to the concentration of free glucose. By measuring the change in hydrogel pressure with a pressure transducer (40), the biosensor (10) is able to accurately measure the concentration of the tree glucose molecule without the problem of oxygen limitations and interference encountered by prior art biosensors.

Abstract: An anti-cancer substance has a porphyrin-like molecule conjugated to an anti-cancer drug. In one embodiment, the porphyrin-like molecule is conjugated directly to an anti-cancer drug. In a second embodiment, the porphyrin-like molecule is conjugated to a first end of a peptide chain, while a second end of the peptide chain is conjugated to the anti-cancer drug. The peptide chain is designed to be cleaved under physiological conditions surrounding the tumor. In the preferred embodiment, the peptide chain functions as a protease inhibitor once it has been cleaved.